GLP-1Separation and Purification Technology Symposium
With the continuous growth in demand for hypoglycemic and weight loss treatments, coupled with the expansion of more indications for chronic diseases, Novo Nordisk's semaglutide and Eli Lilly's tiraparib have become the most sought-after treatments this year. Behind themGLP-1The track has received unprecedented attention.
domesticGLP-1The target track is filled with the smoke of war, and the weight-loss concept stocks in the secondary market have also seen a surge in stock prices amidst the attention of many investors. However, under the fierce competition where the SGLP-2 brand has taken root in people's hearts and telboprost has been approved not long after, how can one find market opportunities?FDA,EMAwarningGLP-1How can we balance security risks?
12month23On the same day, Tongxie United with NavInfo Technology held the “GLP-1The Symposium on Separation and Purification Technology" was specially invited70Industry leaders discuss togetherGLP-1The development strategy aims to assist the local polypeptide drug industry in achieving more substantial development in the future.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event and delivered a keynote speech on 'Analysis of the Current Situation and Development Trends of the Global Peptide Drug Market'.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua pointed out that peptide drugs have high specificity and safety. With the continuous development of synthesis technology and the reduction in production costs, more blockbuster products will emerge. Looking at the development of peptide drugs globally, peptide drugs were initially used in the field of diabetes treatment. However, with the development and innovation of new peptide drugs, their application areas have been continuously expanding. In recent years, they have gradually extended to the field of obesity, achieving an important transformation. In China, peptide drugs have started from insulin and moved towards newGLP1RIn the development of pharmaceuticals, Huadong Medicine's liraglutide has been approved for both diabetes and weight management, aligning with international standards in peptide drug research and development in China.
According to Frost & Sullivan research, in the disease area, oncology and digestive system diseases are developing steadily, while interest in immunology, neurology and reproductive system diseases is on the rise. Among the research and development targetsGLP1RHighest popularity. globalGLP1RThe peptide drug market is growing rapidly,2021Annual achievement170billion US dollars, and it is expected to2030Will reach in908billion dollars.GLP1RThe growth rate of the peptide drug market has driven rapid expansion in this sector.2021Already reached677billion dollars, inGLP1RUnder the continuous impact of peptide drugs, it is expected that the overall peptide drug market2030Annual reach2,108billion dollars. At the same time, the market scale of peptide drugs in China has been increasing year by year with the global market scale, and its proportion in the global peptide drug market scale has remained at a constant level for many years.15%left and right.
The Chinese peptide drug market started relatively late. As of now, a total of37The number of new peptide drugs in China, including multiple peptides5model "Although there are fewer domestically approved peptide drugs, the dual increase in the number of equivalence studies and local companies' clinical applications proves that China's peptide drug industry is booming, and local peptide bulk drugs andCDMO companyLeading enterprises have also developed global competitiveness. Due to China's large population base with broad demand, coupled with limited production capacity of imported products, there is still a significant gap in the demand side. It is expected that with the approval of new products and the launch of generic drugs, the future development space for China's peptide drug market is broad,” Mao Hua said.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging the global think tank resources of Frost & Sullivan and the cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating a wealth of project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
